Comparative Pharmacology
Head-to-head clinical analysis: PENTIDS 250 versus POLYCILLIN PRB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENTIDS 250 versus POLYCILLIN PRB.
PENTIDS '250' vs POLYCILLIN-PRB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting transpeptidase activity and cell wall synthesis, leading to bacterial lysis.
POLYCILLIN-PRB combines ampicillin and probenecid. Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Probenecid inhibits renal tubular secretion of ampicillin, increasing its plasma concentration.
250 mg orally every 8 hours.
250-500 mg orally every 6 hours or 500 mg-1 g intramuscularly every 6-8 hours.
None Documented
None Documented
0.5-1 hour (prolonged in renal impairment; requires dose adjustment when CrCl <30 mL/min)
Terminal elimination half-life: 1-1.5 hours in patients with normal renal function; prolonged to 7-10 hours in anuria.
Primarily renal (60-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal (10-30%)
Renal: 60-80% unchanged via glomerular filtration and tubular secretion; Biliary/fecal: 20-40% as metabolites and unchanged drug.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic